News

New study magnifies the lost opportunity for industry sixfold; the global gap is $564 billion

More doctors are expected to be charged; meanwhile, California e-pedigree meetings restart

WHO meeting bans nongovernmental organizations (NGOs) who advocate for more-comprehensive treaties

Life sciences runners-up include executives of Spectrum Pharmaceuticals, Dohmen Group and Gauthier Biomedical

PBM-sponsored program passes on its discounts from manufacturers

Companies were served subpoenas dating back to 2007

HDMA seminar attendees are skeptical of the project rising sufficiently on Congress' calendars

Cold chain products constitute 10% of SKUs, on average

Maybe not, as biotech companies develop on-the-spot treatments

CVS Caremark updates its list of blocked drugs that will not be available on its formularies, in part to battle manufacturers' copay programs

While the "fiscal cliff" looms over all legislative activity, Congress' agenda for FDA and healthcare is already setting up, says Patton Boggs

New report assesses the progress in adopting both of these marketing techniques

Next-gen SenseAware 2000 is deployed, along with a wider international distribution

Valley had $130 million in 2011 revenue

A new policy debate over drug regulation is emerging as the NECC scandal worsens

Annual survey of leading third-party logistics providers tabulates their interest in serving manufacturers, hospitals and retail

Peer-to-peer consulting and social gaming may catch physicians' attention

InTouch Solutions, MD Mindset collaborate to tailor iPad content development

Here are the factors to consider when deciding to use a third-party logistics provider (3PL)

In the wake of NECC meningitis scandal, a Congressional report documents a decade of regulatory 'gaps' in protecting public health

Visual aids, diminished for a time as a marketing and educational tool because of industry restrictions, are making a comeback

Pricing systems in US drug supply chain have many limitations; an analytics-based method might avoid some of them

New incentives for health plans could alter the way payers review new drugs

Applying the managed services model to commercial operations can result in dramatic savings as pharma companies globalize